solnatide (AP301, TIP)
Permeability edema in Acute Respiratory Distress Syndrome (ARDS), including COVID-19-related ARDS
Key Facts
About APEPTICO
APEPTICO is a clinical-stage biotech leveraging a proprietary peptide platform to target epithelial sodium channels (ENaC) for restoring barrier function in damaged tissues. The company's lead asset, solnatide (AP301/TIP), has advanced to Phase II trials for ARDS and has received significant attention and regulatory support for compassionate use in severe COVID-19. Backed by European Union grants and operating as a private entity, APEPTICO is positioning its platform to address high-unmet-need conditions in critical care and inflammation, though it remains pre-revenue and reliant on further clinical and funding milestones.
View full company profileAbout APEPTICO
APEPTICO is a clinical-stage biotech leveraging a proprietary peptide platform to target epithelial sodium channels (ENaC) for restoring barrier function in damaged tissues. The company's lead asset, solnatide (AP301/TIP), has advanced to Phase II trials for ARDS and has received significant attention and regulatory support for compassionate use in severe COVID-19. Backed by European Union grants and operating as a private entity, APEPTICO is positioning its platform to address high-unmet-need conditions in critical care and inflammation, though it remains pre-revenue and reliant on further clinical and funding milestones.
View full company profileAbout APEPTICO
APEPTICO is a clinical-stage biotech leveraging a proprietary peptide platform to target epithelial sodium channels (ENaC) for restoring barrier function in damaged tissues. The company's lead asset, solnatide (AP301/TIP), has advanced to Phase II trials for ARDS and has received significant attention and regulatory support for compassionate use in severe COVID-19. Backed by European Union grants and operating as a private entity, APEPTICO is positioning its platform to address high-unmet-need conditions in critical care and inflammation, though it remains pre-revenue and reliant on further clinical and funding milestones.
View full company profile